Canada - English - Health Canada

sandoz canada incorporated - hyoscine butylbromide - solution - 20mg - hyoscine butylbromide 20mg - antimuscarinics antispasmodics

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - hyoscine butylbromide, quantity: 10 mg - tablet, sugar coated - excipient ingredients: colloidal anhydrous silica; acacia; white beeswax; calcium hydrogen phosphate dihydrate; stearic acid; maize starch; macrogol 6000; tartaric acid; purified talc; sucrose; povidone; carnauba wax; titanium dioxide; soluble maize starch - spasm of the gastrointestinal tract

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - hyoscine hydrobromide - solution for injection - hyoscine hydrobromide 0.04 % (w/v) - antiemetics and antinauseants

Ireland - English - HPRA (Health Products Regulatory Authority)

martindale pharmaceuticals ltd - hyoscine hydrobromide - solution for injection - 400 microgram(s)/millilitre - other antiemetics

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - hyoscine butylbromide, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - spasm of the gastrointestinal tract, biliary spasm, renal spasm, diagnostic aid in radiology.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - indications as at 23 october 2001: preanaesthetic medication to reduce salivary secretions and bronchial secretions. to prevent cholinergic cardiac effects such as cardiac arrhythmias, hypotension and bradycardia. management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability. concurrent administration with anticholinesterase agents (eg. neostigmine, physostigmine) to block the adverse muscarinic effects of these agents following surgery to terminate curarisation. for poisoning by organophosphate pesticides, atropine may be used concomitantly with a cholinesterase reactivator such as pralidoxime to reverse muscarinic effects.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sunward pharmaceutical sdn. bhd. - hyoscine butylbromide -

Canada - English - Health Canada

omega laboratories limited - hyoscine butylbromide - solution - 20mg - hyoscine butylbromide 20mg - antimuscarinics antispasmodics

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - atropine sulfate monohydrate, quantity: 600 microgram/ml; sodium hydroxide - injection, solution - excipient ingredients: water for injections; sodium chloride; sulfuric acid - indications as at 30 september 2003:surgery : atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialogogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. after surgery atropine may also be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) when used to terminate curarisation to counteract the adverse muscarinic effects of these drugs. cardiopulmonary resuscitation : atropine may be used during cardiopulmonary resuscitation to treat sinus bradycardia and associated hypotension, and increased ventricular irritability. anticholinesterase poisoning : atropine juno is also used in the treatment of sinus bradycardia induced by organophosphate pesticides, amanita muscaria mushrooms or other compounds with anticholinesterase activity. a cholinesterase reactivator, e.g. pralidoxime iodide, may be given concurrently.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - glycopyrronium bromide, quantity: 200 microgram - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. as a preoperative antimuscarinic to reduce salivary, tracheobronchial and pharyngeal secretions, and to reduce the acidity and volume of the gastric contents. ,2. as a preoperative or intra-operative antimuscarinic to attenuate or prevent intraoperative bradycardia associated with the use of suxamethonium or due to cardiac vagal reflexes. ,3. to protect against the peripheral muscarinic actions (e.g. bradycardia and excessive secretions) of anticholinesterases such as neostigmine or pyridostigmine given to reverse neuromuscular blockade produced by non-depolarising muscle relaxants.